🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Aethlon Medical, Inc. AEMD PHARMA

Healthcare · Medical Devices · United States
https://www.aethlonmedical.com
Company Profile ↓
$1.81
-85.28% 1Y
Mkt Cap$1.29M
P/E-0.12
P/B0.16
52W High$79.50
52W Low$1.81
Book Value$10.89
EPS (TTM)$-14.65

Company Overview

Aethlon Medical, Inc., a medical therapeutic company, engages in developing novel immunotherapeutic devices in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device intended to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation, and other disease states. The company was founded in 1984 and is based in San Diego, California.

Why Investors Should Care

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.07.

Growth & Price Performance

Stock Price Performance

1 Year:-85.28%
6 Months:-79.20%
3 Months:-82.17%
1 Month:-42.54%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 0% of range
$1.81 $79.50
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)29.18 · Oversold
Price Performance
1M-42.54%
3M-82.17%
6M-79.20%
1Y-85.28%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

No notable strengths flagged.

CONS

  • Trading 97.7% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-0.12
Industry PE
24.83
Forward P/E
-3.18
PEG Ratio
-
Book Value
$10.89
Price to Book
0.16
P/S
-
EV/EBITDA
0.48
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-
Profit 5Y
-
Revenue (YoY)
-
Earnings (YoY)
-

Profitability & Returns

ROCE
-149.27%
ROE
-
ROA
-76.69%
Profit Margin
0.00%
Op Margin
0.00%
Gross Margin
0.00%
EPS (Latest Qtr)
$-12.25
EPS (TTM)
$-14.65

Balance Sheet & Liquidity

Debt/Equity
0.07
Quick Ratio
4.76
Current Ratio
5.42
Debt
$367.61K
Total Assets
$6.33M
Current Assets
$5.57M
Working Capital
$4.12M

Ownership

Promoter Holding
0.58%
Chg in Prom Hold
-3.18%
FII / Inst Holding
4.34%
Chg in FII Hold
-5.45%

Financial Snapshot

Enterprise Value
$1.29M
Total Revenue (TTM)
$0
EBITDA
$-6.77M
Free Cash Flow
$-4.79M
Operating Cash Flow
$-7.18M
Shares Outstanding
711.14K
Gross Margin
0.00%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 AEMD Aethlon Medical, Inc. PHARMA 1.81 -0.12 $1.29M 0.00% -149.27% - - -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,123.91 37.80 $1.00T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 269.12 31.22 $648.55B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 248.78 70.48 $439.62B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 148.46 118.77 $366.28B 2.31% - 6.96% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 400.84 25.74 $359.79B 2.47% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 137.70 20.80 $261.73B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 160.04 23.99 $248.20B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 603.02 32.49 $222.97B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2013Dec 2013Jun 2014Sep 2014Dec 2014Jun 2015Sep 2015Dec 2015Jun 2016Sep 2016Dec 2016Jun 2017Sep 2017Dec 2017Jun 2018Sep 2018Dec 2018Jun 2019Sep 2019Dec 2019Jun 2020Sep 2020Dec 2020Jun 2021Sep 2021Dec 2021Jun 2022Sep 2022Dec 2022Jun 2023Sep 2023Dec 2023Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -----------------------131.97K131.97K17.12K000------00000
Cost of Revenue ----------------------------------------
Gross Profit ----------------------------------------
Operating Expenses -----------------------------------2.00M1.79M1.51M2.06M1.93M
Operating Income -229.80K-1.23M-1.17M-601.19K-1.09M-1.09M-1.12M-1.08M-1.13M-2.23M-1.24M-1.16M-1.24M-1.16M-1.10M-1.35M-1.96M-1.57M-1.70M-876.41K-1.41M-1.77M-2.44M-2.10M-2.01M-2.53M-2.91M-3.67M-2.85M-3.41M-3.18M-3.57M-2.62M-2.90M--2.00M-1.79M-1.51M-2.06M-1.93M
EBITDA ------------------------------------5.96M-1.71M-1.43M-1.98M-1.69M
Interest Expense ----------------------------------------
Pretax Income ------------------------------------6.25M-1.76M-1.49M-2.02M-1.88M
Tax Provision ----------------------------------------
Net Income -3.35M-2.23M-3.66M-847.41K-1.55M-1.18M-1.22M-1.22M-2.13M-2.26M-1.21M-1.84M-1.30M-1.22M-1.15M-1.39M-2.01M-2.07M-1.71M-819.58K-1.41M-1.77M-2.44M-2.10M-2.01M-2.53M-2.91M-3.81M-2.85M-3.28M-3.03M-3.47M-2.57M-2.81M--6.25M-1.76M-1.49M-2.02M-1.88M
Diluted EPS ------------------------0.16-0.13-0.16-0.19-1.84-1.24-1.35-1.22-1.37-2.76-16.11-50.25--42.50-187.00-12.25-
R&D Expense 293.58K542.38K347.00K250.39K214.16K182.00K207.68K147.80K117.66K333.43K178.44K157.46K168.57K129.21K194.78K178.80K243.84K248.87K222.86K218.57K377.17K508.90K461.18K587.69K478.20K354.57K858.35K852.46K558.22K678.92K628.45K593.40K414.66K261.49K240.20K-524.37K294.32K532.78K-

Profit & Loss (Annual)

Figures in USD.

Metric Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -1.36M1.23M1.62M762.42K886.57K392.07K149.62K229.62K650.19K659.10K-574.25K000
Cost of Revenue ----------------
Gross Profit ----------------
Operating Expenses ------------12.47M12.64M9.34M7.29M
Operating Income -4.56M-3.11M-3.58M-3.06M-3.99M-4.38M-6.10M-4.83M-6.00M-5.93M-7.89M--11.90M-12.64M-9.34M-7.29M
EBITDA -------------11.66M-12.28M-13.04M-6.81M
Interest Expense --------------10.11K14.37K
Pretax Income -------------12.03M-12.21M-13.39M-7.15M
Tax Provision ----------------
Net Income -5.71M-8.11M-4.89M-13.36M-6.80M-4.87M-7.28M-5.68M-6.19M-6.37M-7.89M--12.03M-12.21M-13.39M-7.15M
Diluted EPS -------------2,360.00-1,944.00-428.85-10.61
R&D Expense --1.44M1.51M1.03M782.00K673.00K586.00K896.00K927.00K2.07M2.34M2.75M2.52M2.21M1.91M

Balance Sheet (Annual)

Figures in USD.

Metric Mar 2010Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -567.22K838.69K496.69K1.70M1.38M2.53M1.73M7.35M4.12M10.39M10.67M-17.51M8.25M7.36M6.33M
Current Assets -------------15.09M6.23M5.95M5.57M
Cash & Equivalents ----------9.60M9.86M-14.53M5.44M5.50M5.03M
Inventory -----------------
Receivables ------------127.97K0---
Total Liabilities ---9.64M16.43M729.21K1.03M1.13M1.32M1.82M1.11M1.38M-2.44M2.48M2.24M1.45M
Current Liabilities -6.54M10.13M9.64M15.65M573.98K526.61K611.76K477.96K1.82M1.07M1.38M-1.51M1.83M1.90M1.45M
Long Term Debt -----------------
Total Debt -------------1.21M940.32K649.75K336.72K
Total Equity -4.40M-5.98M-9.30M-9.14M-14.95M615.45K1.55M676.38K6.13M2.43M9.41M9.43M-15.06M5.77M5.12M4.89M
Shares Outstanding -------------5.75K6.57K51.70K314.09K

Cash Flows (Annual)

Figures in USD.

Metric Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -1.97M-1.84M-2.10M-2.14M-5.05M-4.33M-3.51M-3.91M-4.29M-5.20M-6.76M--10.51M-10.13M-7.65M-7.00M
Investing Cash Flow -9.35K-1.74K0-96.06K0-9.31K-16.43K-24.82K0-151.66K-59.88K--943.11K-250.87K0-3.70K
Financing Cash Flow 1.93M1.97M2.08M3.36M4.65M5.61M2.96M9.35M1.15M11.13M7.13M-8.91M1.29M7.73M6.52M
Capital Expenditure -2.54K-1.74K-0-96.06K-0-9.31K-16.43K-24.82K-0-151.66K-59.88K-349.19K-943.11K-250.87K--3.70K
Free Cash Flow -1.97M-1.84M-2.10M-2.24M-5.05M-4.34M-3.52M-3.94M-4.29M-5.35M-6.82M--11.45M-10.38M-7.65M-7.00M
Net Change in Cash -------------2.53M-9.09M81.85K-480.19K

Ratios (Annual)

Figures in %.

Metric Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % ----------------
Operating Margin % --229.1%-290.7%-188.2%-523.7%-494.6%-1,555.4%-3,228.8%-2,612.5%-912.0%-1,197.3%--2,072.0%---
Net Margin % --596.6%-397.7%-822.6%-891.5%-549.6%-1,855.8%-3,795.9%-2,697.8%-980.3%-1,196.6%--2,094.9%---
ROE % 95.6%87.3%53.5%89.4%-1,104.4%-313.8%-1,075.7%-92.6%-255.4%-67.7%-83.6%--79.9%-211.7%-261.3%-146.4%
ROCE % 76.3%33.5%39.1%21.9%-495.0%-219.0%-547.1%-70.3%-260.9%-63.6%-84.9%--74.3%-197.0%-171.1%-149.3%

Shareholding Pattern

Insiders
0.58%
Institutions
4.34%
Public Float
4.37%

Top Institutional Holders

#Holder% HeldSharesValue
1 HRT Financial LP 2.05% 14.55K $91.80K
2 Citadel Advisors Llc 1.21% 8.60K $54.23K
3 Jane Street Group, LLC 1.09% 7.78K $49.07K
4 Shay Capital LLC 0.87% 6.21K $39.21K
5 Virtu Financial LLC 0.78% 5.56K $35.10K
6 Ikarian Capital, LLC 0.40% 2.87K $18.13K
7 Geode Capital Management, LLC 0.29% 2.04K $12.86K
8 Scientech Research LLC 0.28% 2.01K $12.69K
9 UBS Group AG 0.25% 1.77K $11.20K
10 Tower Research Capital LLC (TRC) 0.18% 1.27K $7.99K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for AEMD

Yahoo Finance hu, 13 Aug 2026

Aethlon Medical Reports Q1 Fiscal 2027 Results and Progress on Hemopurifier® Program

Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a clinical-stage medical therapeutic company, today announced financial results for fiscal first quarter ended June 30, 2026, and provided a corporate update.…

Yahoo Finance Mon, 13 Jul 2026

Aethlon Medical Continues to Observe Directional Changes in Second Cohort of Australian Oncology Clinical Trial Evaluating Hemopurifier®

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company developing products to treat cancer and life-threatening viral infections, today announced that patients in the second cohort of its Australian oncology feasibility study d…

Yahoo Finance Mon, 06 Jul 2026

Aethlon Medical Announces Pricing of $4.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced the pricing of its follow-on offering of 5,633,009 shares of its co…

Yahoo Finance Fri, 26 Jun 2026

Aethlon Medical Announces Publication Demonstrating Novel Long COVID Biomarker and Potential Therapeutic Target for the Hemopurifier®

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced publication of new peer-reviewed research in the International Jour…

Yahoo Finance Wed, 17 Jun 2026

Aethlon Medical advances Hemopurifier study as final trial cohort nears completion

Aethlon Medical CEO James Frakes joined Steve Darling from Proactive to discuss the company’s Hemopurifier® technology and the progress of its ongoing clinical program evaluating the device’s potential role in cancer treatment. The Hemopuri…

Yahoo Finance Wed, 17 Jun 2026

Aethlon Medical Inc (AEMD) Q4 2026 Earnings Call Highlights: Strategic Advances Amid Financial ...

Aethlon Medical Inc (AEMD) reports significant progress in clinical trials and cost management, despite ongoing financial hurdles.

AEMD — Frequently Asked Questions

What is the current share price of Aethlon Medical, Inc. (AEMD)?

As of 2026-09-19 21:16 PDT, Aethlon Medical, Inc. (AEMD) trades at $1.81 on NasdaqCM. Its 52-week range is $1.81 to $79.50.

What is the market capitalisation of AEMD?

Aethlon Medical, Inc. (AEMD) has a market capitalisation of $1.29M on NasdaqCM.

What is the P/E ratio of AEMD?

AEMD trades at a trailing price-to-earnings (P/E) ratio of -0.12. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.16.

Is AEMD a good stock to buy?

This page provides a data-driven analysis of Aethlon Medical, Inc. (AEMD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space